Myelodysplastic syndromes (MDS) are treated based on type and risk assessment, but traditional therapies may not work for everyone. Clinical trials offer a way to explore emerging treatments and ...

Recent advances in defining low- and intermediate-risk myelodysplastic syndromes (MDSs) have emphasized the critical role of molecular characterization using next-generation sequencing (NGS).

For over a decade, the standard of care for high-risk MDS has remained a class of drugs called hypomethylating agents (HMAs). Borate notes that despite their continued use, there has been limited ...

On Monday, Good Morning America anchor Robin Roberts announced to viewers that she has been diagnosed with myelodysplastic syndrome, a blood and bone marrow disease once known as preleukemia. Roberts, ...